In the context of the debated association between homocysteine (Hcy) and hypertension, we attempted to isolate possible underlying specific mechanisms, hypothesizing that an inadequately elevated and chronic urinary folate loss secondary to an hypertensive nephroangiosclerotic damage may favour the occurrence of hyperhomocysteinemia.
Plasma Hcy levels are determined by both genetic and acquired factors. A major role in determining high Hcy levels is played by nutritional deficiencies of B vitamins (folate, vitamin B 12 , and vitamin B 6 ), renal insufficiency and homozygosity for 677C4T mutation on methylene-tetrahydrofolate reductase (MTHFR) gene.
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In recent years, an association between Hcy and hypertension has been suggested, even if the finding is object of controversy and the pathogenetic mechanism(s) is still unclear. 3 Brattstrom et al., 4 put forward the view that impaired renal function owing to hypertension and atherosclerosis is an important cause of elevated plasma Hcy found in vascular disease patients, even in patients with reduced glomerular filtration rate (GFR) but still normal creatinine. An inverse relationship between GFR and plasma tHcy levels has long been reported by several cross-sectional studies; 5 however, the mechanism underlying this relationship is still debated. Urinary excretion is not a physiological route of Hcy disposal, as more than 99% of filtered Hcy is subject to tubular reabsorption; 6 conversely, metabolic disturbances by uraemic toxins in Hcy remethylation and transsulphuration pathways could be implicated. 7 Folate is a major determinant of Hcy levels and is an essential vitamin that serves as a cofactor in onecarbon transfer for DNA synthesis. 8 Most plasma folate is in the form of 5-methyltetrahydrofolate and the amount of protein binding of folate in plasma is too small to prevent glomerular filtration of the vitamin, resulting in an estimated filtration of more than 1 mg/day of folate. As this value is at least 20 times higher than that measured in urines, an efficient renal reabsorption is necessary to maintain plasma folate concentration. As folate reabsorption occurs primarily in the proximal tubule, [8] [9] [10] and it is dependent on the extension of tubular cell surface, 11 hypertensive nephropathy involving glomerular and tubular damage could affect vitamin re-uptake, finally resulting in an increased urinary folate excretion.
Objective of our study was to verify if urinary folate loss was increased in patients with minimal or overt hypertensive nephropathy. We, therefore, analysed urinary folate excretion in 20 patients with an angiographical diagnosis of renal artery stenosis (RAS), a classical model of hypertension associated with ischaemic nephropathy, and in 40 essential hypertensive (EH) patients with different degrees of renal damage. To avoid variability owing to the different glomerular load of plasma folate to be filtered, patients were selected for having similar levels of plasma folate: the 40 EH patients were selected among 90 hypertensive patients in whom a renovascular hypertension was ruled out, in order to define a a case-control study in a 2:1 ratio, with two EH patients matched for folate levels with each RAS patient.
The study was approved by our institutional review board and informed consent was obtained from all of the patients.
Hcy, folate, creatinine, MTHFR 677C4T polymorphism were evaluated as described previously.
2,12 For the urinary folate assay, 24 h urine collection was performed and urine was stored in a 2 l acid washed plastic containers acidified with 3 g ascorbate. Urine aliquots were stored at À201C until analysis. Urinary folate concentration was analysed by an automated chemiluminescence method, adapted from the plasma assay (Immulite 2000; DPC, Los Angeles, CA, USA). Before measurement, urine samples were diluted to reach concentrations similar to those of plasma. The within-and betweenassay coefficient of variations were 3.1 and 6.3%, respectively. To assess the amount of folate excreted with urine relative to the amount filtrated by the kidney we calculated fractional excretion of folate as fFE (%) ¼ (100 Â folate clearance)/creatinine clearance (cl-creatinine). Folate clearance (cl-folate) was calculated from the formula ((urinary volume Â urinary folate concentration)/serum folate) and expressed in ml/min.
Compared with EH subjects, RAS patients were characterized by lower cl-creatinine (43.37717. 6 According to the distribution of cl-creatinine tertiles, a gradient of Hcy levels (19.46, 14.96 and 12.26 mmol/l, P ¼ 0.001) and fFE (11.12, 4.75 and 3.44, Po0.01) was observed throughout the subgroups, with higher fFE values in the group of patients with lower GFR (Figure 1, Supplementary  Table 2 ). Similarly, according to the distribution of fFE tertiles, a gradient of Hcy levels was found with higher levels in patients with higher fFE (13.41, 14.98 and 18.02 mmol/l, Po0.05) (Supplementary  Figure 1) .
Vitamin B 12 and MTHFR genotype distribution did not differ among the cl-creatinine tertiles groups, as well as between RAS and EH, suggesting that these factors could not significantly influence the observed Hcy differences. Similar considerations applied to plasma folate because of the peculiar method of selection of the patients.
The most relevant result of the present study was that a disproportionately elevated amount of folate was excreted in urine for GFR unit (as expressed by fFE) in patients with nephroangiosclerotic damage.
If the glomerular filtration and the tubular reabsorption are the two determinants of urinary folate excretion, then in conditions of renal insufficiency the expected urinary folate loss will be reduced to the same extent of GFR. Our data show for the first time that this is not the case and that urinary folate loss does not parallel GFR in nephroangiosclerotic patients. For this reason, a defect in tubular folate reabsorption has to be necessarily admitted.
Although no direct proof was collected, it is possible to argue that, in our patients with mild or moderate renal impairment, plasma folate levels may decline over time if the vitamin dietary intake changes for any reason. This could imply an increased vitamin requirement and, in turn, a greater susceptibility to develop hyperhomocysteinemia for hypertensive patients with renal ischaemic damage.
To the best of our knowledge this is the first attempt to study urinary folate loss in hypertensive subjects with a wide range of GFR impairment. If our results will be confirmed in further studies, dietary folate requirements should be revised and vitamin supplementation possibly considered as part of the therapy of patients with hypertensive nephroangiosclerosis. What is known about this topic? K An association between homocysteine and hypertension has been suggested but pathogenetic mechanism(s) remains unclear 4 K Folate and renal function are major determinants of homocysteine levels 1 K Renal tubular re-uptake of filtered folate is essential for the vitamin preservation [9] [10] [11] What this study adds? K In hypertensive patients with nephroangiosclerotic damage, a higher amount of folate is excreted with urine relative to the amount filtered by the kidney; thus, a defect in tubular folate reabsorption has to be admitted K These results could contribute to clarify the mechanism linking hyperhomocysteinemia and hypertensive nephropathy
